Abstract
Positron emission tomography (PET) has routinely been performed as a hybrid imaging method with computed tomography (CT) for attenuation correction and anatomical localization. However, in the last decade, PET imaging has been utilized with magnetic resonance imaging (MRI) instead of CT in the evaluation of organs that is needed a high soft tissue resolution, firstly in research and in the last years in clinical practice. Since MRI is the gold standard method of the evaluation of liver malignancies, liver tumors have become one of the most interested malignancies for the potential of the hybrid PET/MRI systems. In this review we aimed to present the literature of PET/MRI in liver tumors with case examples.
Keywords: Liver tumors, positron emission tomography, magnetic resonance imaging
References
Mayerhoefer ME, Prosch H, Beer L, et al. PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. Eur J Nucl Med Mol Imaging. 2020;47:51-60.
Tan GJ, Berlangieri SU, Lee ST, Scott AM. FDG PET/CT in the liver: lesions mimicking malignancies. Abdom Imaging. 2014;39:187-195.
Hope TA, Fowler KJ, Sirlin CB, et al. Hepatobiliary agents and their role in LI-RADS. Abdom Imaging. 2015;40:613-625.
Lu RC, She B, Gao WT, et al. Positron-emission tomography for hepatocellular carcinoma: Current status and future prospects. World J Gastroenterol. 2019;25:4682-4695.
Murakami K. FDG-PET for hepatobiliary and pancreatic cancer: Advances and current limitations. World J Clin Oncol. 2011;2:229-236.
Hectors SJ, Wagner M, Besa C, Huang W, Taouli B. Multiparametric FDG-PET/MRI of hepatocellular carcinoma: initial experience. Contrast Media Mol Imaging. 2018;2018:5638283.
Bonekamp S, Jolepalem P, Lazo M, Gulsun MA, Kiraly AP, Kamel IR. Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data. Radiology. 2011;260:752-761.
Kim HO, Kim JS, Shin YM, Ryu JS, Lee YS, Lee SG. Evaluation of metabolic characteristics and viability of lipiodolized hepatocellular carcinomas using 18F-FDG PET/CT. J Nucl Med. 2010;51:1849-1856.
Kim SH, Won KS, Choi BW, et al. Usefulness of F-18 FDG PET/CT in the evaluation of early treatment response after interventional therapy for hepatocellular carcinoma. Nucl Med Mol Imaging. 2012;46:102-110.
Chen W, Zhuang H, Cheng G, Torigian DA, Alavi A. Comparison of FDG-PET, MRI and CT for post radiofrequency ablation evaluation of hepatic tumors. Ann Nucl Med. 2013;27:58-64.
Fowler KJ, Maughan NM, Laforest R, et al. PET/MRI of hepatic 90Y microsphere deposition determines ındividual tumor response. Cardiovasc Intervent Radiol. 2016;39:855-864.
Cascales-Campos PA, Romero PR, Schneider MA, et al. Positron emission tomography/computed tomography in patients with hepatocellular carcinoma undergoing liver transplantation. Useful, necessary or irrelevant? Eur J Radiol. 2017;91:155-159.
Hennedige TP, Neo WT, Venkatesh SK. Imaging of malignancies of the biliary tract- an update. Cancer Imaging. 2014;14:14.
American Society for Gastrointestinal Endoscopy (ASGE) Standards of Practice Committee; Anderson MA, Appalaneni V, Ben-Menachem T, et al. The role of endoscopy in the evaluation and treatment of patients with biliary neoplasia. Gastrointest Endosc. 2013;77:167-174.
Jiang L, Tan H, Panje CM, Yu H, Xiu Y, Shi H. Role of 18F-FDG PET/CT imaging in intrahepatic cholangiocarcinoma. Clin Nucl Med. 2016;41:1-7.
Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. Value of PET/CT in the management of primary hepatobiliary tumors, part 2. AJR Am J Roentgenol. 2011;197:W260-W265.
Choi EK, Yoo IeR, Kim SH, et al. The clinical value of dual-time point 18F-FDG PET/CT for differentiating extrahepatic cholangiocarcinoma from benign disease. Clin Nucl Med. 2013;38:e106-e111.
Prytz H, Keiding S, Björnsson E, et al. Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology. 2006;44:1572-1580.
Vilgrain V. Staging cholangiocarcinoma by imaging studies. HPB (Oxford). 2008;10:106-109.
Reid KM, Ramos-De la Medina A, Donohue JH. Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg. 2007;11:671-681.
Mekeel KL, Hemming AW. Surgical management of gallbladder carcinoma: a review. J Gastrointest Surg. 2007;11:1188-1193.
Oe A, Kawabe J, Torii K, et al. Distinguishing benign from malignant gallbladder wall thickening using FDG-PET. Ann Nucl Med. 2006;20:699-703.
Lomis KD, Vitola JV, Delbeke D, et al. Recurrent gallbladder carcinoma at laparoscopy port sites diagnosed by positron emission tomography: implications for primary and radical second operations. Am Surg. 1997;63:341-345.
Low G, Tho LM, Leen E, et al. The role of imaging in the pre-operative staging and post-operative follow-up of rectal cancer. Surgeon. 2008;6:222-231.
van Kessel CS, van Leeuwen MS, van den Bosch MA, et al. Accuracy of multislice liver CT and MRI for preoperative assessment of colorectal liver metastases after neoadjuvant chemotherapy. Dig Surg. 2011;28:36-43.
Kulemann V, Schima W, Tamandl D, Kaczirek K, Gruenberger T, Wrba F, Weber M, Ba-Ssalamah A. Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI? Eur J Radiol. 2011;79:e1-e6.
Llamas-Elvira JM, Rodríguez-Fernández A, Gutiérrez-Sáinz J, et al. Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:859-867.
Sotoudeh H, Sharma A, Fowler KJ, McConathy J, Dehdashti F. Clinical application of PET/MRI in oncology. J Magn Reson Imaging. 2016;44:265-276.
Reiner CS, Stolzmann P, Husmann L, et al. Protocol requirements and diagnostic value of PET/MR imaging for liver metastasis detection. Eur J Nucl Med Mol Imaging. 2014;41:649-658.
Hong SB, Choi SH, Kim KW, et al. Diagnostic performance of [18F]FDG-PET/MRI for liver metastasis in patients with primary malignancy: a systematic review and meta-analysis. Eur Radiol. 2019;29:3553-3563.
Schulz A, Viktil E, Godt JC, et al. Diagnostic performance of CT, MRI and PET/CT in patients with suspected colorectal liver metastases: the superiority of MRI. Acta Radiol. 2016;57:1040-1048.
Berzaczy D, Giraudo C, Haug AR, et al. Whole-body 68Ga-DOTANOC PET/MRI versus 68Ga-DOTANOC PET/CT in patients with neuroendocrine tumors: a prospective study in 28 patients. Clin Nucl Med. 2017;42:669-674.
Jackson T, Darwish M, Cho E, Nagatomo K, Osman H, Jeyarajah DR. 68Ga-DOTATATE PET/CT compared to standard imaging in metastatic neuroendocrine tumors: a more sensitive test to detect liver metastasis? Abdom Radiol (NY). 2021;46:3179-3183.
Desai K, Watkins J, Woodward N, Quigley AM, Toumpanakis C, Bomanji J, Caplin M. Use of molecular imaging to differentiate liver metastasis of colorectal cancer metastasis from neuroendocrine tumor origin. J Clin Gastroenterol. 2011;45:e8-e11.
Sawicki LM, Deuschl C, Beiderwellen K, et al. Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT. Eur Radiol. 2017;27:4091-4099.
